[go: up one dir, main page]

TR199901904T2 - 3-pyridyl enantiomers and their use as analgesics. - Google Patents

3-pyridyl enantiomers and their use as analgesics.

Info

Publication number
TR199901904T2
TR199901904T2 TR1999/01904T TR9901904T TR199901904T2 TR 199901904 T2 TR199901904 T2 TR 199901904T2 TR 1999/01904 T TR1999/01904 T TR 1999/01904T TR 9901904 T TR9901904 T TR 9901904T TR 199901904 T2 TR199901904 T2 TR 199901904T2
Authority
TR
Turkey
Prior art keywords
formula
analgesics
enantiomers
pyridyl
relates
Prior art date
Application number
TR1999/01904T
Other languages
Turkish (tr)
Inventor
W. Holladay Mark
P. Arneric Stephen
Bai Hao
J. Dart Michael
Lin Nan-Horng
K. Lynch John
Sun Or Yat
B. Ryther Keith
P. Sullivan James
T. Wasicak James
P. Ehrlich Paul
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of TR199901904T2 publication Critical patent/TR199901904T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMÜL (I).Bu bulus memelilerde ve yine bu kapsama giren insanlarda agrinin denetim altina alinmasina yönelik bir yöntemle ilgili olup, buna ihtiyaç duyan memeliye ya da hastaya formül (I) e özgü seçkin bilesiklerin ya da bunlarin farmasötik açidan geçerli bir tuzunun verilmesini içerir. Bulus ayrica, analjezik olarak yararli ve ayni zamanda nöronal hücre ölümünü önleyen ve antienflamatuvar olan formül (I) e özgü seçkin (R) ve (S) bilesikleriyle ilgilidir.FORMULA (I). This invention relates to a method of controlling pain in mammals and also in humans within this scope, which includes the administration of selected compounds of formula (I) or a pharmaceutically acceptable salt thereof to the mammal or patient in need. The invention also relates to the exclusive (R) and (S) compounds of formula (I) that are analgesically useful and also prevent anti neuronal cell death and are anti-inflammatory.

TR1999/01904T 1996-12-10 1997-12-10 3-pyridyl enantiomers and their use as analgesics. TR199901904T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76327896A 1996-12-10 1996-12-10
US3232196P 1996-12-10 1996-12-10

Publications (1)

Publication Number Publication Date
TR199901904T2 true TR199901904T2 (en) 1999-10-21

Family

ID=26708255

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01904T TR199901904T2 (en) 1996-12-10 1997-12-10 3-pyridyl enantiomers and their use as analgesics.

Country Status (21)

Country Link
EP (1) EP0950057B1 (en)
JP (2) JP4272261B2 (en)
KR (2) KR100472154B1 (en)
CN (1) CN1125064C (en)
AT (1) ATE227717T1 (en)
AU (1) AU733881B2 (en)
BG (1) BG64196B1 (en)
BR (1) BR9714677A (en)
CA (2) CA2273917C (en)
DE (1) DE69717148T2 (en)
DK (1) DK0950057T3 (en)
ES (1) ES2189003T3 (en)
HU (1) HUP0001110A3 (en)
IL (1) IL130083A0 (en)
NO (1) NO992705L (en)
NZ (1) NZ335810A (en)
PL (1) PL333920A1 (en)
PT (1) PT950057E (en)
SK (1) SK75999A3 (en)
TR (1) TR199901904T2 (en)
WO (1) WO1998025920A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510619A (en) 1998-04-02 2002-04-09 アール・ジェイ・レイノルズ・タバコ・カンパニー Pharmaceutical composition and use thereof
US6054451A (en) * 1998-04-21 2000-04-25 Algos Pharmaceutical Corporation Analgesic composition and method for alleviating pain
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6103911A (en) * 1999-06-15 2000-08-15 Abbott Laboratories Process for reduction of (2R)-4-oxoazetidinone-2-carboxylic acid
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04011206A (en) * 2002-05-15 2005-02-14 Abbott Lab Treatment of neuropathic pain.
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
CN101321761A (en) 2005-12-09 2008-12-10 霍夫曼-拉罗奇有限公司 Tricyclic amide derivatives for the treatment of obesity
TW200800020A (en) * 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
DE102007058504A1 (en) 2007-12-05 2009-07-09 Acino Ag Transdermal therapeutic system containing a modulator of nicotinic acetylcholine receptors (nAChR)
JP2012505834A (en) 2008-10-14 2012-03-08 サイコジェニックス・インコーポレーテッド Nicotinic acetylcholine receptor ligands and uses thereof
AR075988A1 (en) * 2009-04-09 2011-05-11 Lilly Co Eli PIRIDYLOXI COMPOUND - PIRROLIDINE INHIBITOR OF RECOVERY OF SEROTONINE AND NOREPINEFRINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC PAIN
US8474529B2 (en) * 2009-04-09 2013-07-02 Regency Technologies Llc Control of concentric tubing direction
EP2727604A4 (en) 2011-06-30 2015-03-18 Toray Industries Antipruritic agent
CA2944179A1 (en) 2013-03-27 2014-10-02 Georgetown University 2-halo-5-alkynyl-pyridyl nicotinic ligands
CN110944689B (en) 2017-06-07 2022-12-09 施菲姆德控股有限责任公司 Intravascular fluid movement devices, systems, and methods of use
EP3710076B1 (en) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
WO2019152875A1 (en) 2018-02-01 2019-08-08 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
WO2020028537A1 (en) 2018-07-31 2020-02-06 Shifamed Holdings, Llc Intravascaular blood pumps and methods of use
US12220570B2 (en) 2018-10-05 2025-02-11 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
EP3996797A4 (en) 2019-07-12 2023-08-02 Shifamed Holdings, LLC Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (en) 2019-08-07 2023-08-30 Calomeni, Michael CATHETER BLOOD PUMPS AND COLLAPSIBLE PUMP HOUSINGS
WO2021062270A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
WO2021062265A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
WO2021119478A1 (en) 2019-12-11 2021-06-17 Shifamed Holdings, Llc Descending aorta and vena cava blood pumps

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301702D0 (en) * 1983-01-21 1983-02-23 Shell Int Research Azetidine compounds
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab 3 - pyridyloxy (or thio) alkyl heterocyclic compounds, pharmaceutical compositions containing them and their uses in the preparation of medicaments for controlling chemical synaptic transmission
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

Also Published As

Publication number Publication date
ES2189003T3 (en) 2003-07-01
HUP0001110A2 (en) 2001-04-28
AU5601098A (en) 1998-07-03
BG103556A (en) 2000-06-30
DK0950057T3 (en) 2003-03-10
JP2009143924A (en) 2009-07-02
KR100422995B1 (en) 2004-03-12
CA2273917C (en) 2010-05-25
NO992705D0 (en) 1999-06-03
JP4272261B2 (en) 2009-06-03
BR9714677A (en) 2000-10-03
CA2698384A1 (en) 1998-06-18
CA2698384C (en) 2012-05-01
CA2273917A1 (en) 1998-06-18
KR100472154B1 (en) 2005-02-21
EP0950057A1 (en) 1999-10-20
DE69717148T2 (en) 2003-10-02
JP2001504857A (en) 2001-04-10
BG64196B1 (en) 2004-04-30
CN1125064C (en) 2003-10-22
PL333920A1 (en) 2000-01-31
JP5364872B2 (en) 2013-12-11
SK75999A3 (en) 2000-05-16
WO1998025920A1 (en) 1998-06-18
DE69717148D1 (en) 2002-12-19
NO992705L (en) 1999-08-03
CN1245496A (en) 2000-02-23
PT950057E (en) 2003-04-30
EP0950057B1 (en) 2002-11-13
AU733881B2 (en) 2001-05-31
HUP0001110A3 (en) 2002-04-29
ATE227717T1 (en) 2002-11-15
KR20040004476A (en) 2004-01-13
KR20000069399A (en) 2000-11-25
NZ335810A (en) 2001-03-30
IL130083A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
TR199901904T2 (en) 3-pyridyl enantiomers and their use as analgesics.
ATE244564T1 (en) FELBAMAT DERIVATIVES
TR200100047T2 (en) Thiobenzimidazole derivatives
TR199801315T2 (en) Use of a ppar-alpha and ppar-gamma antagonist for the treatment of syndrome X.
TR199801195T2 (en) Quinoline and quinosil compounds useful in therapy.
TR200001279T2 (en) Poly (ADP-ribose) polymerase ("PARP") inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue damage.
DK0662958T3 (en) 1- (2-Oxoacetyl) piperidine-2-carboxylic acid derivatives as multi-drug resistant cancer cell sensitizers
BG105880A (en) Compounds useful as anti-inflammatory agents
DE60027564D1 (en) TEK ANTAGONISTS
TR200101343T2 (en) Alkynyl-substituted quinolin-2-one derivatives as agents used against cancer
YU21401A (en) Tetrahydropyridoethers
BG106586A (en) Pyrazolopyramidines as therapeutic agents
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
TR199800027T1 (en) Difenilmethylene piperidin t�revleri.
TR199701535T1 (en) Use of bis-1,2,4-triazoles in the manufacture of a drug for the treatment of cancers.
IS5985A (en) Cells-suppressing inflammatory-destroying and immunosuppressive compounds
DE60040753D1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL FAULT EXPOSURES
TR199900336T2 (en) Tetrahydroquinoline derivatives as EAA antagonists.
TR199801268T2 (en) 3-Azetidinylalkylpiperidines or pyrrolidines as tachykinin antagonists.
TR199902257T2 (en) Tetrahidropirido bile�ikleri
DE69614149D1 (en) Quinoline derivatives as antimalarial agents
ATE386742T1 (en) IMIDAZONAPHTHYRIDINES
DK1032556T3 (en) Pharmaceutically active compounds and methods of use
BR0208860A (en) Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs